Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Cited In for PubMed (Select 10371503)

1.

Epigenetic heterogeneity in HIV-1 latency establishment.

Matsuda Y, Kobayashi-Ishihara M, Fujikawa D, Ishida T, Watanabe T, Yamagishi M.

Sci Rep. 2015 Jan 9;5:7701. doi: 10.1038/srep07701.

2.

Plasmodium infection reduces the volume of the viral reservoir in SIV-infected rhesus macaques receiving antiretroviral therapy.

Zhan XY, Wang N, Liu G, Qin L, Xu W, Zhao S, Qin L, Chen X.

Retrovirology. 2014 Dec 9;11(1):112. [Epub ahead of print]

3.

Fetal exposure to HIV-1 alters chemokine receptor expression by CD4+T cells and increases susceptibility to HIV-1.

Bunders MJ, van Hamme JL, Jansen MH, Boer K, Kootstra NA, Kuijpers TW.

Sci Rep. 2014 Oct 24;4:6690. doi: 10.1038/srep06690.

4.

Finding a cure for human immunodeficiency virus-1 infection.

Blankson JN, Siliciano JD, Siliciano RF.

Infect Dis Clin North Am. 2014 Dec;28(4):633-50. doi: 10.1016/j.idc.2014.08.007. Epub 2014 Sep 30.

PMID:
25277513
5.

Modeling the timing of antilatency drug administration during HIV treatment.

Petravic J, Martyushev A, Reece JC, Kent SJ, Davenport MP.

J Virol. 2014 Dec;88(24):14050-6. doi: 10.1128/JVI.01701-14. Epub 2014 Sep 24.

PMID:
25253352
6.

HIV-1 latency in monocytes/macrophages.

Kumar A, Abbas W, Herbein G.

Viruses. 2014 Apr 22;6(4):1837-60. doi: 10.3390/v6041837. Review.

7.

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.

Battistini A, Sgarbanti M.

Viruses. 2014 Apr 14;6(4):1715-58. doi: 10.3390/v6041715. Review.

8.

A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region.

Zhang Y, Fan M, Geng G, Liu B, Huang Z, Luo H, Zhou J, Guo X, Cai W, Zhang H.

Retrovirology. 2014 Mar 12;11:23. doi: 10.1186/1742-4690-11-23.

9.

Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir.

Moniuszko M, Liyanage NP, Doster MN, Parks RW, Grubczak K, Lipinska D, McKinnon K, Brown C, Hirsch V, Vaccari M, Gordon S, Pegu P, Fenizia C, Flisiak R, Grzeszczuk A, Dabrowska M, Robert-Guroff M, Silvestri G, Stevenson M, McCune J, Franchini G.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):115-26. doi: 10.1089/AID.2013.0220.

PMID:
24432835
10.

A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG.

Clin Infect Dis. 2014 Mar;58(6):883-90. doi: 10.1093/cid/cit813. Epub 2013 Dec 12.

11.

An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Trinité B, Ohlson EC, Voznesensky I, Rana SP, Chan CN, Mahajan S, Alster J, Burke SA, Wodarz D, Levy DN.

J Virol. 2013 Dec;87(23):12701-20. doi: 10.1128/JVI.01939-13. Epub 2013 Sep 18.

12.

Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Klatt NR, Chomont N, Douek DC, Deeks SG.

Immunol Rev. 2013 Jul;254(1):326-42. doi: 10.1111/imr.12065. Review.

13.

HIV/AIDS eradication.

Marsden MD, Zack JA.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4003-10. doi: 10.1016/j.bmcl.2013.05.032. Epub 2013 May 18. Review.

14.

In vivo effects of antiviral protein kinase C modulators on zebrafish development and survival.

Davis RV, McKernan LN, Rhodes J, Kulkosky J.

ISRN Toxicol. 2011 Dec 20;2011:248280. doi: 10.5402/2011/248280. Print 2011.

15.

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, Østergaard L, Søgaard OS, Tolstrup M.

PLoS One. 2013 Apr 26;8(4):e62074. doi: 10.1371/journal.pone.0062074. Print 2013.

16.

From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication.

Shan L, Siliciano RF.

Bioessays. 2013 Jun;35(6):544-52. doi: 10.1002/bies.201200170. Epub 2013 Apr 24. Review.

17.

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.

Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS.

Hum Vaccin Immunother. 2013 Apr;9(4):790-9. doi: 10.4161/hv.23202. Epub 2013 Apr 1. Review.

18.

Lost in transcription: molecular mechanisms that control HIV latency.

Taube R, Peterlin M.

Viruses. 2013 Mar 21;5(3):902-27. doi: 10.3390/v5030902. Review.

19.

Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.

Fernandez G, Zaikos TD, Khan SZ, Jacobi AM, Behlke MA, Zeichner SL.

J Virol. 2013 Apr;87(7):3966-78. doi: 10.1128/JVI.03251-12. Epub 2013 Jan 30.

20.

An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection.

Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, Cron RQ, van der Sluis RM, Jeeninga RE, Berkhout B, Kutsch O.

J Virol. 2013 Feb;87(4):2264-77. doi: 10.1128/JVI.01594-12. Epub 2012 Dec 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk